ArticleCureus2025
Diagnostic and Critical Care Challenges in Rapidly Progressive Interstitial Lung Disease Secondary to Multiple Myeloma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The concurrent presentation of multiple myeloma (MM) and interstitial lung disease (ILD) remains exceptionally rare, with limited literature describing optimal management strategies for this dual pathology. We report a complex case of a 62-year-old male with newly diagnosed MM with intermediate-risk cytogenetics (del13q, gain 1q) who concurrently presented with rapidly progressive ILD demonstrating a usual interstitial pneumonia (UIP) pattern. The patient's 6-month clinical course was marked by multi-organ involvement, recurrent infections, thromboembolic complications, and multiple cardiopulmonary crises culminating in a fatal outcome. This case illustrates the profound diagnostic and therapeutic challenges when dual malignancy and progressive pulmonary fibrosis coexist, highlighting the need for aggressive multidisciplinary management, heightened awareness of infection risk, and early consideration of palliative care discussions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.